Motilal oswal midcap Fund worst performing Midcap Fund 2025-2026 Review by Drstocks (Mutual fund Specialist)

Motilal Oswal Midcap Fund Review 2026

From Market Leader to Recent Underperformer – Should Investors Continue Their SIP?

By DrStocks Research™

Research Beyond Returns

📌  Title

Motilal Oswal Midcap Fund Review 2026 | Returns, Portfolio, Risk Analysis & DrStocks Rating 

📌 Description

Independent review of Motilal Oswal Midcap Fund with latest NAV, returns, CAGR, benchmark comparison, portfolio analysis, risk metrics and DrStocks Fund Score. 

@Motilal Oswal MF

📌 Focus Keyword

Motilal Oswal Midcap Fund Review

⭐ DrStocks Fund Score™

Parameter    Rating

⭐ Overall Score  75 /100

📈 Investment View  HOLD

💰 Fresh Investment  SIP Preferred

⚠ Riskometer  🔴 Very High

⏳ Investment Horizon 7–10 Years

🔄 Review Frequency Quarterly

📊 Data Confidence High

📌 30-Second Verdict

Motilal Oswal Midcap Fund was among the best-performing mid-cap funds during the 2020–2024 bull market. However, recent performance has lagged the benchmark. While the fund's investment philosophy remains intact, investors should focus on long-term consistency rather than reacting to one year of underperformance. SIP investors may continue with discipline, whereas fresh lump-sum investors may prefer staggered investments. 

Insta link   30sec summary 

 https://www.instagram.com/reel/DaTEmXcyAbZ/?igsh=c214Mm01M2ZqM2J6

@Motilal Oswal MF

⚡ Fast Facts

Particular  Latest Data

Fund Category  Mid Cap Fund

Benchmark  Nifty Midcap 150 TRI

Launch Date  24 Feb 2014

Latest NAV (Direct)  ₹109.27

AUM  ₹36,458 Crore

Expense Ratio (Direct) 0.76%

Minimum SIP ₹500

Exit Load

1% (as per scheme terms)

Riskometer

🔴 Very High

@Motilal Oswal MF +1

📊 Returns Snapshot

Period   Fund    Benchmark

1 Year   -6.82%    7.30%

3 Year  19.32%  22.12%

5 Year  22.98%  19.20%

@Motilal Oswal MF

📊 Key Statistics

Parameter  Value

NAV  ₹109.27

AUM  ₹36,458 Cr

Expense Ratio 0.76%

Sharpe Ratio 0.62

Beta 0.93

Standard Deviation 20.30

Risk Level Very High

💡 DrStocks Insight

The fund delivered exceptional returns during the 2020–2024 growth cycle, attracting significant investor inflows.

 More recently, its growth-oriented investment style has lagged as market leadership shifted. Rather than focusing solely on recent returns, investors should evaluate whether the underlying investment process remains robust over a complete market cycle.

✅ What We Like

Large AUM of ₹36,458 Crore

Competitive expense ratio

High-conviction portfolio

Strong long-term wealth creation track record

Suitable for disciplined long-term SIP investors

❌ What We Don't Like

Recent underperformance versus benchmark

Higher volatility

Risk-adjusted returns below category average

Not suitable for short-term investors

⭐ Final Verdict

Motilal Oswal Midcap Fund remains a credible active mid-cap fund for investors with a long investment horizon and the ability to tolerate volatility. Although recent returns have disappointed relative to the benchmark, one weak period alone does not invalidate the fund's long-term investment process. Investors should continue monitoring portfolio quality, relative performance, and consistency before making major allocation changes.

👨‍💼 About the Author

Dr. Niraj Deogade

Founder – DrStocks Research™

AMFI Registered Mutual Fund Distributor

ARN – 327968

DrStocks Research™ focuses on evidence-based mutual fund research, portfolio analysis, and investor education to help individuals make informed long-term investment decisions

.

📞 Contact DrStocks

🌐 Website: www.drstocks.in⁠

📧 Email: shrinetrainvestments@gmail.com

📱 Mobile / WhatsApp: +91 9420075865

ARN: 327968